The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
A randomized phase 3 study was performed to investigate the efficacy and safety of maintenance therapy with S‐1 after induction therapy with carboplatin plus S‐1 in patients with advanced squamous non–small cell lung cancer (NSCLC).
Methods
Chemotherapy‐naive patients with advanced or relapsed squamous NSCLC were treated with carboplatin (area under the curve of 5 on day 1 every 3 weeks)...
BACKGROUND
Preclinical studies suggested that the addition of bevacizumab could overcome acquired resistance (AR) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The aim of this study was to evaluate the clinical efficacy and safety of a combination of afatinib and bevacizumab after AR.
METHODS
Patients with EGFR‐mutant non–small cell lung cancer after AR were enrolled...
BACKGROUNDA previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S‐1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first‐line treatment for advanced non–small cell lung cancer (NSCLC). In the current study, the authors evaluated the efficacy and safety of combined S‐1, carboplatin, and bevacizumab followed by...
BACKGROUND:The objective of this study was to investigate whether the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer TNM classification (TNM7) had superior discriminatory ability over the sixth edition of the TNM classification (TNM6) in patients with gastric cancer regardless of their country of origin.
METHODS:In total, 538 patients from the Kanagawa...
BACKGROUND:To improve the efficacy of radiofrequency ablation (RFA) for the treatment of intermediate‐sized hepatocellular carcinomas (HCCs), the authors compared RFA combined with transcatheter arterial chemoembolization (TACE) to RFA alone.
METHODS:The authors randomly assigned 37 patients with solitary HCCs (diameter, 3.1‐5.0 cm in the greatest dimension) to 2 groups: the TACE‐RFA group, in which...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.